

DESCRIPTION

Source *E. coli*-derived
Phe21-Gly104
Accession # Q96QR1

N-terminal Sequence Analysis Phe21

Predicted Molecular Mass 8.2 kDa

SPECIFICATIONS

SDS-PAGE 6 kDa, reducing conditions

Activity Measured by the ability of the immobilized protein to support the adhesion of the A549 human lung carcinoma cells. The ED₅₀ for this effect is 0.15-0.75 µg/mL.

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Formulation Lyophilized from a 0.2 µm filtered solution in PBS. See Certificate of Analysis for details.

PREPARATION AND STORAGE

Reconstitution Reconstitute at 250 µg/mL in PBS.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

BACKGROUND

High in Normal-1 (HIN-1), also known as Uteroglobin related protein 2 (UGRP2), is an 8 kDa secreted protein of the secretoglobin superfamily (SCGB3A1) (1). HIN-1 is expressed in bronchial epithelial and secretory Clara cells, mammary epithelial cells (particularly during pregnancy), salivary glands, and the prostate (2-5). It is up-regulated in Clara cells by IL-4, IL-13, Oncostatin M, EGF, and TGF-α and down-regulated by IFN-α, β, and γ (6-9). It is secreted into bronchial lavage fluid, saliva, and plasma, and may form disulfide-linked dimers (10). HIN-1 binds to the macrophage scavenger receptor MARCO, and to the surface of mammary and bronchial epithelial cells (11, 12). HIN-1 promotes apoptosis and inhibits the proliferation, migration, and invasion of breast cancer cells (12). The down-regulation of HIN-1 expression in many breast, lung, and prostate cancers correlates with hypermethylation of its promoter (4, 10, 13, 14). Mature human HIN-1 shares 58% and 62% aa sequence identity with mouse and rat HIN-1, respectively (4).

References:

1. Mukherjee, A.B. *et al.* (2007) *Endocr. Rev.* **28**:707.
2. Porter, D. *et al.* (2002) *Mech. Dev.* **114**:201.
3. Reynolds, S.D. *et al.* (2002) *Am. J. Respir. Crit. Care Med.* **166**:1498.
4. Krop, I. *et al.* (2001) *Proc. Natl. Acad. Sci.* **98**:9796.
5. Niimi, T. *et al.* (2002) *Cytogenet. Genome Res.* **97**:120.
6. Yamada, A. *et al.* (2005) *J. Immunol.* **175**:5708.
7. Tomita, T. *et al.* (2009) *Am. J. Respir. Cell Mol. Biol.* **40**:620.
8. Yamada, A. and S. Kimura (2005) *FEBS Lett.* **579**:2221.
9. Yamada, A. *et al.* (2009) *Biochem. Biophys. Res. Commun.* **379**:964.
10. Krop, I. *et al.* (2004) *Mol. Cancer Res.* **2**:489.
11. Bin, L.-H. *et al.* (2003) *J. Immunol.* **171**:924.
12. Krop, I. *et al.* (2005) *Cancer Res.* **65**:9659.
13. Krop, I. *et al.* (2003) *Cancer Res.* **63**:2024.
14. Shigematsu, H. *et al.* (2005) *Int. J. Cancer* **113**:600.